What urinary catecholamine and metanephrine levels are measured to diagnose a suspected pheochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Urinary Levels of Pheochromocytoma

For diagnosing pheochromocytoma, measure 24-hour urinary fractionated metanephrines (metanephrine and normetanephrine) and catecholamines (norepinephrine, epinephrine, and dopamine), with fractionated metanephrines being the most diagnostically reliable urinary test. 1, 2

Specific Urinary Tests to Order

Primary Urinary Tests

  • 24-hour urinary fractionated metanephrines (metanephrine and normetanephrine): Sensitivity 77-97%, specificity 69-98% 1
  • 24-hour urinary total metanephrines: Sensitivity approximately 95% 2, 3
  • 24-hour urinary catecholamines (norepinephrine, epinephrine, dopamine): Traditional test but lower sensitivity 1

Additional Urinary Marker

  • Urinary metanephrine to creatinine ratio: Sensitivity 100% 3

Test to Avoid

  • Do NOT use vanillylmandelic acid (VMA) for screening - it has poor diagnostic reliability (only 38% in one study) and should not be used 1, 2, 3, 4

Diagnostic Thresholds

A 24-hour urine total metanephrine level above 1,800 mg (or μg) in the appropriate clinical setting is almost always diagnostic for pheochromocytoma. 1

For fractionated metanephrines, using a cut-off of twice the upper limit of normal provides optimal diagnostic performance with 95% sensitivity and 92.3% specificity 5. The sum of metanephrine and normetanephrine (urineMNM) ≥0.43 mg/24h yields 89% sensitivity and 96% specificity 6.

Important Collection Requirements

  • Measure 24-hour urine creatinine concomitantly to confirm accurate collection 2
  • Collect urine over a full 24-hour period for optimal sensitivity
  • Multiple collections (2-3 consecutive days) may be needed for intermittent-secreting tumors 4

Comparison with Plasma Testing

While plasma free metanephrines have the highest overall sensitivity (97-100%) and specificity (85-89%) and are considered the best initial screening test 1, urinary measurements remain highly valuable because:

  • Urinary tests have a lower false-positive rate compared to plasma tests 1
  • They integrate catecholamine production over 24 hours, capturing episodic secretion
  • They are more practical when proper plasma collection (supine position for 30 minutes) cannot be ensured 7
  • Recent evidence shows plasma and urine metanephrines can be used interchangeably with good correlation 8

Common Pitfalls to Avoid

Medications That Cause False Positives

Discontinue these medications before testing to eliminate false-positive results 1:

  • Tricyclic antidepressants
  • Decongestants
  • Amphetamines
  • Reserpine
  • Phenoxybenzamine
  • Acetaminophen (interferes with certain measurement methods)

Clinical Situations Causing False Positives

  • Acute illness or hospitalization 7
  • Severe physiological stress
  • Improper collection technique

When Results Are Borderline

If urinary metanephrine levels are only mildly elevated (less than 2-fold the upper limit):

  1. Repeat the 24-hour urine collection to confirm results 3
  2. Consider clonidine suppression test with plasma normetanephrine measurements 1, 2, 3, 9
  3. Alternatively, measure plasma free metanephrines for additional confirmation 2, 3
  4. In low-risk settings with borderline results, adopt a wait-and-retest approach after 6 months to detect progressive increases 7

Additional Biochemical Marker

For patients with suspected malignant pheochromocytoma or dopamine-secreting tumors, plasma methoxytyramine (MTY) provides useful information, though urine MTY is not helpful as it derives from renal DOPA metabolism rather than tumor production 10, 11.

References

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Research

[Strategy for the biochemical study of pheochromocytoma].

Annales de medecine interne, 1983

Research

Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors.

Hypertension research : official journal of the Japanese Society of Hypertension, 2018

Guideline

pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Research

Update on the diagnosis of the pheochromocytoma.

Hipertension y riesgo vascular, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.